# An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)

> **NCT01442064** · NA · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 608 (actual)

## Conditions studied

- Macular Edema
- Retinal Vein Occlusion

## Interventions

- **DRUG:** Ranibizumab 0.5 mg

## Key facts

- **NCT ID:** NCT01442064
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2012-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01442064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01442064, "An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01442064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*